National Health (Price and Special Patient Contribution) Amendment Determination 2013 (No. 2) (No. PB 15 of 2013)

Link to law: https://www.comlaw.gov.au/Details/F2013L00559

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now
 
PB 15 of 2013
National Health (Price and Special Patient Contribution) Amendment Determination 2013 (No. 2)1
National Health Act 1953
I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this Determination under section 85B of the National Health Act 1953.
Dated                                                              21 March 2013
 
 
 
 
 
 
 
 
 
FELICITY McNEILL
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing
 
1          Name of Instrument
            (1)        This Instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2013 (No. 2).
            (2)        This Instrument may also be cited as PB 15 of 2013.
2          Commencement
            This Instrument commences on 1 April 2013.
3          Amendment of the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010)
            Schedule 1 amends the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010).
Schedule 1     Amendments
 
[1]      Schedule 1, entry for Candesartan in the form Tablet containing candesartan cilexetil 8 mg
(a)           omit from the column headed “Determined Price”:     6.27        substitute:             5.11
(b)           omit from the column headed “Claimed Price”:          8.65        substitute:             7.26
[2]      Schedule 1, entry for Candesartan in the form Tablet containing candesartan cilexetil 16 mg
(a)           omit from the column headed “Determined Price”:     18.19     substitute:             15.28
(b)           omit from the column headed “Claimed Price”:          20.82     substitute:             17.49
[3]      Schedule 1, entry for Candesartan in the form Tablet containing candesartan cilexetil 32 mg
(a)           omit from the column headed “Determined Price”:     24.48     substitute:             18.47
(b)           omit from the column headed “Claimed Price”:          26.80     substitute:             20.80
[4]      Schedule 1, entry for Eprosartan in the form Tablet 400 mg (as mesylate)
(a)           omit from the column headed “Determined Price”:     6.85        substitute:             5.75
(b)           omit from the column headed “Claimed Price”:          8.27        substitute:             6.95
[5]      Schedule 1, entry for Eprosartan in the form Tablet 600 mg (as mesylate)
(a)           omit from the column headed “Determined Price”:     17.15     substitute:             14.41
(b)           omit from the column headed “Claimed Price”:          18.77     substitute:             15.77
[6]      Schedule 1, entry for Erythromycin in the form Tablet 400 mg (as ethyl succinate)
(a)           omit from the column headed “Determined Price”:     3.45        substitute:             4.56
(b)           omit from the column headed “Claimed Price”:          5.61        substitute:             6.72
[7]      Schedule 1, entry for Indomethacin
omit from the column headed “Claimed Price”:          3.25        substitute:             3.42
[8]     Schedule 1, entry for Levonorgestrel with Ethinyloestradiol in the form Pack containing 21 tablets
150 micrograms-30 micrograms and 7 inert tablets [Microgynon 30 ED]
(a)           omit from the column headed “Determined Price”:     8.55        substitute:             7.18
(b)           omit from the column headed “Claimed Price”:          19.54     substitute:             16.41
[9]     Schedule 1, entry for Levonorgestrel with Ethinyloestradiol in the form Pack containing 21 tablets
150 micrograms-30 micrograms and 7 inert tablets [Nordette 28]
(a)           omit from the column headed “Determined Price”:     8.55        substitute:             7.18
(b)           omit from the column headed “Claimed Price”:          19.50     substitute:             16.38
[10]  Schedule 1, entry for Levonorgestrel with Ethinyloestradiol in the form Pack containing 6 tablets 50 micrograms-30 micrograms,
5 tablets 75 micrograms-40 micrograms, 10 tablets 125 micrograms-30 micrograms and 7 inert tablets [Triphasil 28]
(a)           omit from the column headed “Determined Price”:     8.55        substitute:             7.18
(b)           omit from the column headed “Claimed Price”:          19.50     substitute:             16.38
[11]  Schedule 1, entry for Levonorgestrel with Ethinyloestradiol in the form Pack containing 6 tablets 50 micrograms-30 micrograms,
5 tablets 75 micrograms-40 micrograms, 10 tablets 125 micrograms-30 micrograms and 7 inert tablets [Triquilar ED]
(a)           omit from the column headed “Determined Price”:     8.55        substitute:             7.18
(b)           omit from the column headed “Claimed Price”:          19.54     substitute:             16.41
[12]    Schedule 1, entry for Methyldopa
omit from the column headed “Claimed Price”:          8.21        substitute:             8.89
[13]    Schedule 1, entry for Mometasone in the form Cream containing mometasone furoate 1 mg per g, 15 g
(a)           omit from the column headed “Determined Price”:     6.06        substitute:             5.09
(b)           omit from the column headed “Claimed Price”:          8.85        substitute:             7.43
[14]    Schedule 1, entry for Mometasone in the form Lotion containing mometasone furoate 1 mg per g, 30 mL
(a)           omit from the column headed “Determined Price”:     9.55        substitute:             8.02
(b)           omit from the column headed “Claimed Price”:          12.34     substitute:             10.37
[15]    Schedule 1, entry for Mometasone in the form Ointment containing mometasone furoate 1 mg per g, 15 g
(a)           omit from the column headed “Determined Price”:     6.06        substitute:             5.09
(b)           omit from the column headed “Claimed Price”:          8.85        substitute:             7.43
[16]    Schedule 1, after entry for Norfloxacin
insert:
Nystatin
Oral suspension 100,000 units per mL, 24 mL
Oral
Nilstat
1
3.81
5.44
[17]    Schedule 1, entry for Olmesartan in the form Tablet containing olmesartan medoxomil 20 mg
(a)           omit from the column headed “Determined Price”:     8.84        substitute:             7.43
(b)           omit from the column headed “Claimed Price”:          10.45     substitute:             8.78
[18]    Schedule 1, entry for Olmesartan in the form Tablet containing olmesartan medoxomil 40 mg
(a)           omit from the column headed “Determined Price”:     18.76     substitute:             15.76
(b)           omit from the column headed “Claimed Price”:          20.38     substitute:             17.12
[19]    Schedule 1, entry for Sulfasalazine
omit from the column headed “Claimed Price”:          20.99     substitute:             21.06
[20]    Schedule 1, entry for Telmisartan in the form Tablet 40 mg
(a)           omit from the column headed “Determined Price”:     6.27        substitute:             5.27
(b)           omit from the column headed “Claimed Price”:          8.29        substitute:             6.96
[21]    Schedule 1, entry for Telmisartan in the form Tablet 80 mg
(a)           omit from the column headed “Determined Price”:     18.19     substitute:             15.28
(b)           omit from the column headed “Claimed Price”:          20.21     substitute:             16.98
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003.  See http://www.comlaw.gov.au